bluuebunny/crossref_metadata_2025_split huggingface dataset:
New ultrasound-guided L5 selective nerve root block puncture approach for the treatment of pain due to high-iliac-crest lumbar disc herniation: A case report
Authors: Gao Weiwei , Zeng Jie , Wang Min , Tang Li , Yang Hao , Wang Yanan , Li Wei 
Published: November 2024

Rationale:
Lumbar 5 (L5) selective nerve root block is a common treatment for lumbar 4/5 disc herniation. It is difficult to perform real-time ultrasound-guided targeted L5 nerve root block because of the deep structure of the L5/S1 intervertebral foramen and the occlusion of the sacrum and ilium. Therefore, the safe and efficient implementation of L5 nerve root block is very important for improving the clinical promotion and use of this procedure.

Patient concerns:
A 43-year-old male, who presented with a 1-month history of lumbosacral and left lower limb pain.

Diagnoses:
The characteristic manifestation of pain symptoms was continuous and distending-like pain, accompanied by numbness on the posterior side of the left lower limb. The pain could be exacerbated by prolonged standing, sedentary behavior, and turning over while being relieved by lying down to rest. The visual analog score was 7 triggered by innocuous stimuli, configuring a clinical picture of typical protrusion of the lumbar intervertebral disc. Physical examination: muscle tenderness, straight leg-raising test of the left lower limb was 60° (+), test of supinating and throwing out one’s belly (+), and Achilles tendon reflex (‐).

Interventions:
The patient underwent an ultrasound-guided L5 nerve root block with a modified puncture approach technique called the “transverse process-zygapophysis separation method.”

Outcomes:
The patient had a successful nerve blockade characterized by significant reduction in pain after the operation.

Lesson:
The innovative puncture approach method may be considered a therapeutic option in patients with chronic pain.
RNA-binding protein biomarkers NR4A2 and NR4A3 in renal ischemia–reperfusion injury diagnosis
Authors: Chen Junrui , Chen Ximing , Zhang Keqin 
Published: November 2024

Background:
The diagnosis of renal ischemia and reperfusion injury (RIRI) is crucial for renal transplant recipients. RNA-binding proteins (RBPs) may have an impact on disease development. Therefore, this study explored the biomarkers associated with RBPs in RIRI.

Methods:
The RIRI related datasets, GSE37838 and GSE43974, and 3964 RBPs were employed in this research. The differential expression analysis was implemented for RIRI and control to gain differentially expressed genes in GSE37838. Then, differentially expressed genes were overlapped with RBPs to acquire intersection genes. Further, the machine learning, diagnostic analysis, and expression validation were executed to filtered biomarkers for RIRI. Additionally, pathway enrichment, molecular networks, and drug prediction were proceed.

Results:
The area under the curve values of NR4A2 and NR4A3 were >0.7, as well as the expression trend was consistent in both datasets, and all of them were remarkably highly expressed in RIRI. Therefore, they were considered as biomarkers of RIRI. Enrichment analyses revealed that they were both associated with neuroactive ligand–receptor interactions, among others. Further, the lncRNA–miRNA–mRNA and transcription factors (TF)–mRNA network was constructed, revealing that they were all regulated by noncoding RNAs and TF, such as SNHG5-hsa-mir-10b-5p-NR4A3, CREB1, TFAP2A, etc. In addition, a large number of biomarker-related drugs were predicted, among which cadmium acetate, potassium chromate (VI), etc were associated with NR4A2 and NR4A3.

Conclusion:
In this study, we identified biomarkers associated with RBPs in RIRI, explored their associated pathways and drugs, which provided new insights into the clinical diagnosis and treatment of RIRI.
A child with factor V deficiency with a novel F5 gene mutation misdiagnosed as a left iliac fossa abscess: A case report
Authors: Zhang Yifan , Liu Lu , Guo Qin , Li Yiyuan , Luo Shuanghong , Wan Chaomin , Zhu Yu 
Published: November 2024

Rationale:
Congenital factor V deficiency is classified as a rare bleeding disorder that is expressed in an autosomal recessive manner and generally occurs in 1 in a million people. This disorder is accompanied by a variety of clinical manifestations, which can easily lead to misdiagnosis. This is the first report to identify the factor V gene variant c.2439delC (p.I814Lfs*23) in exon 13.

Patient concerns:
A 13-year-old boy was admitted with a suspected left iliac fossa abscess. He had been previously diagnosed with and underwent management for a left iliac fossa abscess at a local hospital. The patient was treated with antibiotics and underwent surgical excision; however, his left iliac fossa mass reappeared. Platelet count and function, prothrombin time, and activated partial thromboplastin time were all normal.

Diagnoses:
The patient was considered to have congenital factor V deficiency following the measurement of coagulation factor activity, and the diagnosis was confirmed by genetic testing.

Interventions:
The mass was diagnosed as an abscess and the patient was treated with antibiotics at the local hospital. Surgical resection was performed, after which the mass was identified as a hematoma. The patient was then transferred to our hospital for treatment with fresh frozen plasma (FFP) infusion.

Outcomes:
The left iliac fossa mass stopped growing and the coagulation function exhibited a significant improvement. At discharge, the patient was recommended to seek medical help before any surgical intervention or following trauma, and when a deep hemorrhage is identified, the patient should undergo timely infusion with FFP.

Lessons:
This case report presents a rare occurrence of congenital factor V deficiency resulting in a left iliac fossa hematoma mistaken for an abscess, which resulted in unnecessary antibiotic therapy and surgery. This case emphasizes that coagulation factor deficiency should be highly suspected for joint mass combined with coagulation dysfunction.
Effects of the umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis: A systematic review and meta-analysis
Authors: Xiao Zhijian , Wang Xinying , Li Cheng , Luo Lihua , Li Wei 
Published: November 2024

Background:
This study aimed to evaluate the effects of umbilical cord mesenchymal stem cells (UC-MSCs) in the treatment of knee osteoarthritis.

Methods:
PubMed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure and Wanfang databases were searched from inception to March 31, 2024. RevMan 5.3 was used to conduct meta-analyses of the final included studies.

Results:
Three randomized controlled studies were conducted. Western Ontario and McMaster Universities Osteoarthritis Index was reduced in the UC-MSCs group compared that in to the control group (mean difference: ‐25.85; 95% confidence interval: −41.50, −10.20; P = .001). Knee Lysholm Score was improved in the UC-MSCs group compared with the control group (mean difference: 18.33; 95% confidence interval: 12.89, 23.77; P < .00001). Egger test showed P = .583, indicating no publication bias. Sensitivity analysis indicated that the results were stable.

Conclusion:
Intra-articular injection of UC-MSCs improved function and reduced pain in patients with knee osteoarthritis. However, the number of included studies was small and more studies are needed to confirm this.
Comparison of a fixed-dose combination of Celecoxib/PG201 [Layla®] versus co-administration of individual formulations in healthy participants: A randomized trial
Authors: Song Ji Hye , Koh Hyunsook , Moon Hyun-Young , Jung Jin-Gyu , Hong Jang Hee , Sunwoo Jung 
Published: November 2024

Background:
Osteoarthritis (OA) is a prevalent joint disease affecting the spine, hands, hips, knees, and feet. However, definitive drugs for OA are lacking, and current treatments are limited owing to inconvenient administration, inadequate functional improvement, and long-term side effects including gastrointestinal and cardiovascular adverse events. Therefore, in this study, we aimed to assess the pharmacokinetics and safety profiles of PK101, a fixed-dose combination (FDC) comprising PG201, a 12-herb extract used in OA treatment in traditional East Asian medicine, and celecoxib, a selective cyclooxygenase-2 inhibitor, by comparing its administration as an FDC and the corresponding individual formulations in healthy subjects.

Patients and methods:
A randomized, open-label, single-dose, 2 × 2 crossover design with a cohort of healthy participants. All subjects received a single FDC tablet (405.4 mg PG201 and 100 mg celecoxib) or the individual formulations, with 7-day washout period between administrations. The estimation of maximum plasma concentration and area under the plasma concentration–time curve from time zero to the time of the last quantifiable concentration of celecoxib involved determining the geometric mean ratios and 90% confidence intervals of the FDC compared to its individual formulations.

Results:
Forty-six participants were enrolled; however, only 44 completed the study. The geometric mean ratios (90% confidence intervals) for the area under the plasma concentration–time curve from time zero to the time of the last quantifiable concentration and maximum plasma concentration of celecoxib were 1.1124 (1.0601–1.1672) and 1.2788 (1.1708–1.3969), respectively. The time of maximum plasma concentration range was 1.0 to 4.0 hours and 1.0 to 6.0 hours (minimum–maximum) for the FDC and individual formulations, respectively. Seven adverse events occurred in 6 subjects.

Conclusion:
The systemic exposure and safety profiles of the individual and FDC formulations were similar, supporting their potential as an innovative and effective therapeutic approach for OA treatment. All relevant data are within the paper and its Supporting Information files.
Causal relationship between sleep characteristics and thyroid function: A bidirectional Mendelian randomization study
Authors: Jia Zonghang , Li Zhonghui , Li Yujie 
Published: November 2024

Background:
Previous researches have revealed some links between thyroid function and sleep characteristics, however it remains unclear which one causes the other. The purpose of this study was to investigate the potential causal relationship between hyperthyroidism, hypothyroidism, and sleep characteristics.

Methods:
We utilized aggregated data from published genome-wide association studies (GWAS) to select genetic instruments for sleep variables. The 5 sleep-related traits (chronotype, short sleep duration, long sleep duration, daytime sleepiness, and insomnia) were associated with distinct genetic variants chosen as instrumental factors. Employing MR Egger’s analysis of Mendelian randomization (MR), weighted median, weighted mode, and inverse variance weighted (IVW) methods to assess the 5 sleep traits in relation to hyperthyroidism and hypothyroidism, we subsequently conducted inverse MR analysis to examine the causal relationship between thyroid function and the 5 sleep characteristics.

Results:
The IVW technique did not reveal a causal association between chronotype, short sleep duration, long sleep duration, daytime sleepiness, or insomnia and the risk of abnormal thyroid function in the study investigating the influence of sleep characteristics on this risk. The outcomes of the IVW approach were consistent with the remaining 3 methods. The IVW, weighted median, MR Egger, and weighted mode methods in the reverse magnetic resonance imaging investigation did not yield evidence of a causative association between the risk of time type, long sleep duration, and insomnia and abnormal thyroid function. In contrast, the weighted median and weighted mode methods showed a possible causal relationship between hypothyroidism and short sleep duration and daytime sleepiness. Sensitivity analyses showed that the results were robust and no pleiotropy or heterogeneity was detected.

Conclusion:
More precisely, our analysis did not uncover any indication of a reciprocal causal link between thyroid function and genetically predicted sleep characteristics.
The association between age-related macular degeneration and risk of Parkinson disease: A systematic review and meta-analysis
Authors: Meng Mingxian , Shen Xiaoming , Xie Yanming , Wang Jiabin , Liu Junhong 
Published: November 2024

Background:
Numerous cohort studies have explored the association between age-related macular degeneration (AMD) and Parkinson disease (PD). However, a comprehensive meta-analysis on this topic is currently lacking. This study aims to address this gap by conducting a meta-analysis of existing cohort studies to investigate the relationship between AMD and the risk of developing PD.

Methods:
Relevant studies were systematically identified through thorough searches of the PubMed, Web of Science, Embase, and Cochrane Library databases. Two investigators independently conducted data extraction. Cohort studies meeting the eligibility criteria and providing risk and precision estimates regarding AMD and the risk of PD were included. Pooled hazard ratio (HR) accompanied by 95% confidence interval (CI) were calculated using either a random-effects model or a fixed-effects model. Sensitivity analyses, involving the exclusion of 1 study at a time, were performed to assess the robustness of the findings. Publication bias was evaluated using Egger test.

Results:
Five studies were included, encompassing a total of 4,771,416 individuals. Among these, 128,771 individuals had AMD, while 4,642,645 individuals did not. The pooled analysis revealed a significant increase in the risk of developing PD for individuals with age-related macular degeneration (hazard ratio [HR] = 1.44; 95% confidence interval [CI]: 1.22–1.71; I
2 = 47.3%). Sensitivity analysis confirmed the robustness of the results. For the exploration of the relationship between nAMD and the risk of developing PD, 2 cohorts were included. The pooled analysis demonstrated a significantly elevated risk of PD for individuals with nAMD (HR = 2.21; 95% CI: 1.55–3.16; I
2 = 0%).

Conclusion:
This meta-analysis suggests a significant association between AMD and an increased risk of PD. These findings offer fresh perspectives on PD’s etiology and pathogenesis, but should be interpreted with caution given the limitations in establishing causality.
Serum LINC01133 combined with CEA and CA19-9 contributes to the diagnosis and survival prognosis of gastric cancer
Authors: Sui Xiaomei , Zhang Qifu , Hao Meili , Chen Yanfang 
Published: November 2024

Background:
Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are currently 2 major diagnostic biomarkers for gastric cancer (GC). The aims of study were to detect the expression of long intergenic nonprotein coding RNA 1133 (LINC01133), and to evaluate its diagnostic and prognostic value in GC. Furthermore, the clinical performance of the joint detection of LINC01133, CEA and CA19-9 was also evaluate in GC.

Methods:
The data were collected from 156 GC, 96 chronic superficial gastritis, 77 chronic atrophic gastritis patients and 89 healthy controls. LINC01133 expression was determined by quantitative real-time PCR. Receiver operating characteristics analysis was used to evaluate the diagnostic value of LINC01133, CEA, CA19-9 individually and jointly. Kaplan–Meier method and log-rank test were used to conduct survival comparison analysis. Cox regression was used to screen the independent prognostic factors for GC.

Results:
Serum LINC01133 expression was decreased in GC patients compared with chronic superficial gastritis, chronic atrophic gastritis and healthy controls, and had considerable diagnostic potential, and notably, the joint detection of LINC01133, CEA, and CA19-9 showed the highest diagnostic accuracy in distinguishing GC patients from healthy or gastritis patients. LINC01133 expression was associated with GC patients’ CEA and CA19-9 levels, tumor size, differentiation, lymph node metastasis and tumor node metastasis stage. Low LINC01133 was associated with poor GC survival, and was an independent prognostic factor for GC.

Conclusion:
Decreased serum LINC01133 had considerable diagnostic potential, and the joint detection of LINC01133, CEA, and CA19-9 might be a more efficient diagnostic strategy for GC patients. Reduced LINC01133 served as a prognostic biomarker to predict poor GC survival.
Clinical risk factors to predict prognosis in wake-up stroke patients: A retrospective study
Authors: Xu Qiwu , Hu Miaomiao , Tan Guoxiang , Zhao Yong , Yin Hao , Ding Ting , Zhou Ying 
Published: November 2024

This study aimed to develop and validate a clinical risk model based on clinical factors to predict prognosis in patients with wake-up stroke (WUS) after multimodal magnetic resonance imaging combined with recombinant tissue plasminogen activator intravenous thrombolysis. The study enrolled 263 patients with WUS, who were divided into the training (n = 162) and validation cohorts (n = 101). In the training cohort, patients were stratified based on modified Rankin Scale (mRS) score at 90 days after thrombolysis, with mRS ≤ 2 indicating a good prognosis (n = 117), and mRS > 2 indicating a poor prognosis (n = 45). Multivariate regression analyses were employed to identify independent risk factors and develop clinical risk models. The performance and stability of the clinical risk model were evaluated using receiver operating characteristic analysis and Hosmer–Lemeshow test. The clinical risk nomogram was constructed based on this model, and evaluated using decision curve analyses. Patients with poor prognosis showed a higher proportion of hyperlipidemia and diabetes and showed a higher levels of National Institute of Health Stroke Scale (NIHSS) at admission, NIHSS at 24 hours, triglyceride, and total cholesterol. Diabetes (odds ratio [OR] = 3.823), hyperlipidemia (OR = 7.361), NIHSS at admission (OR = 5.399), NIHSS at 24 hours (OR = 2.869), triglyceride (OR = 13.790), and total cholesterol (OR = 9.719) were independent predictors of poor prognosis in patients with WUS. Hosmer–Lemeshow test showed that the clinical risk model had a good fit in the training (χ
2 = 19.573, P = .726) and validation cohorts (χ

2
= 19.573, P = .726). The clinical risk model had an area under the curve value of 0.929 (95% confidence interval, 0.886–0.978) in the training cohort and 0.948 (0.906–0.989) in the validation cohort. The decision curve analysis indicated clinical risk nomogram has application value. The clinical risk model can effectively predict WUS prognosis outcomes.
Is intralymphatic immunotherapy effective and safe for allergic rhinitis?: A meta-analysis
Authors: Liu Liangrong , Liang Yacheng , Yan Le , Li Zhiyong 
Published: November 2024

Background:
As there is much controversy in using intralymphatic immunotherapy (ILIT) as a therapeutic means for allergic rhinitis (AR), its efficacy and safety for AR were investigated based on a systematic review and meta-analysis.

Methods:
Databases PubMed, Embase, Cochrane library, and Web of Science were employed to retrieve relevant randomized control studies on ILIT for AR. The search deadline was September 15, 2023. Meta-analysis was performed on the data of the included literature using Stata 15.0.

Results:
Eleven randomized control studies were included involving a total of 406 patients. Meta-analysis results revealed that ILIT improved patients’ quality of life [standardized mean difference (SMD) = ‐0.53, 95% confidence interval (CI) = (‐1.00, ‐0.050)], and reduced the adverse events of nasal symptoms [risk ratio (RR) = 0.16, 95% CI = (0.06, 0.45)] as compared to control, whereas no significant difference was discovered in symptom score [SMD = 0.14, 95% CI = (‐0.34, 0.62)], IgE [SMD = 0.93, 95% CI = (‐0.44, 2.30)], medication scores [SMD = 1.37, 95% CI = (‐0.45, 3.18)], comprehensive symptom and medication scores [SMD = 0.93, 95% CI = (‐0.62, 2.47)], nasal symptoms [RR = 0.16, 95% CI = (0.06, 0.45)], and lymphadenectasis [RR = 2.27, 95% CI = (0.37, 6.73)] versus control.

Conclusion:
After the application of the ILIT strategy against AR, the quality of life of patients was improved and the incidence of adverse events associated with nasal symptoms was reduced, but the conclusion needed further verification with more high-quality research.
Efficacy and safety of percutaneous mechanical circulatory support in patients with cardiogenic shock following acute myocardial infarction: A meta-analysis of randomized controlled trials
Authors: Tariq Muhammad Daoud , Jain Hritvik , Khan Abdul Moiz , Shahnoor Syeda , Goyal Priya , Zulfiqar Eeshal , Ahsan Areeba , Jaiswal Vikash , Daoud Mohamed , Sohail Amir Humza 
Published: November 2024

Background:
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI) with high mortality rates. While mechanical circulatory support devices like intra-aortic balloon pump (IABP) and Impella are used to manage CS, their comparative effectiveness remains unclear. This meta-analysis aims to evaluate the safety and efficacy of Impella in the treatment of AMI-associated CS.

Methods:
A comprehensive literature search was performed across PubMed, EMBASE, Google Scholar, SCOPUS, and Web of Science. The primary efficacy endpoint was 6-month all-cause mortality. Secondary efficacy endpoints included 30-day mortality, major bleeding, limb ischemia, sepsis, and left ventricular ejection fraction. Pooled odds ratios (OR) and standardized mean difference (SMD) with 95% confidence intervals (CIs) were calculated using the random-effects model via Revman version 5.4. Statistical significance was determined at P < .05.

Results:
Four RCTs with a total of 442 patients were included in this meta-analysis. The pooled analysis showed that the odds of 6-month all-cause mortality were significantly lower with Impella compared to standard of care (OR: 0.64, 95% CI: 0.43–0.95; P value: .03). However, 30-day mortality reported no statistically significant difference between the 2 groups (OR: 1.03; 95% CI: 0.43–2.48; P = .95). Our analysis found that the use of impella is associated with a statistically significant increase in the odds of major bleeding (OR: 3.61; 95% CI: 1.14–11.40; P = .03), limb ischemia (OR: 4.91; 95% CI: 1.37–17.59; P = .01), and sepsis (OR: 2.75; 95% CI: 1.25–6.08; P = .01). No statistical significance was found in left ventricular ejection fraction at follow-up between the 2 groups (SMD: −0.35; 95% CI: −0.78 to 0.07; P = .11).

Conclusion:
Impella significantly reduces 6-month all-cause mortality in patients with CS following AMI compared to standard of care. However, this survival benefit is offset by a substantial increase in major bleeding, limb ischemia, and sepsis risks associated with Impella. Future large scale trials are needed to validate these findings and refine clinical guidelines for the optimal use of Impella in treating CS.